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Articles
Quantifying risks and interventions that have affected 
the burden of lower respiratory infections among children 
younger than 5 years: an analysis for the Global Burden of 
Disease Study 2017
GBD 2017 Lower Respiratory Infections Collaborators*
Summary
Background Despite large reductions in under-5 lower respiratory infection (LRI) mortality in many locations, the 
pace of progress for LRIs has generally lagged behind that of other childhood infectious diseases. To better inform 
programmes and policies focused on preventing and treating LRIs, we assessed the contributions and patterns of risk 
factor attribution, intervention coverage, and sociodemographic development in 195 countries and territories by 
drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) LRI estimates.
Methods We used four strategies to model LRI burden: the mortality due to LRIs was modelled using vital registration 
data, demographic surveillance data, and verbal autopsy data in a predictive ensemble modelling tool; the incidence 
of LRIs was modelled using population representative surveys, health-care utilisation data, and scientific literature in 
a compartmental meta-regression tool; the attribution of risk factors for LRI mortality was modelled in a counterfactual 
framework; and trends in LRI mortality were analysed applying changes in exposure to risk factors over time. In GBD, 
infectious disease mortality, including that due to LRI, is among HIV-negative individuals. We categorised locations 
based on their burden in 1990 to make comparisons in the changing burden between 1990 and 2017 and evaluate the 
relative percent change in mortality rate, incidence, and risk factor exposure to explain differences in the health loss 
associated with LRIs among children younger than 5 years.
Findings In 2017, LRIs caused 808 920 deaths (95% uncertainty interval 747 286–873 591) in children younger than 
5 years. Since 1990, there has been a substantial decrease in the number of deaths (from 2 337 538 to 808 920 deaths; 
65·4% decrease, 61·5–68·5) and in mortality rate (from 362·7 deaths [330·1–392·0] per 100 000 children to 
118·9 deaths [109·8–128·3] per 100 000 children; 67·2% decrease, 63·5–70·1). LRI incidence declined globally 
(32·4% decrease, 27·2–37·5). The percent change in under-5 mortality rate and incidence has varied across locations. 
Among the risk factors assessed in this study, those responsible for the greatest decrease in under-5 LRI mortality 
between 1990 and 2017 were increased coverage of vaccination against Haemophilus influenza type b (11·4% decrease, 
0·0–24·5), increased pneumococcal vaccine coverage (6·3% decrease, 6·1–6·3), and reductions in household air 
pollution (8·4%, 6·8–9·2).
Interpretation Our findings show that there have been substantial but uneven declines in LRI mortality among 
countries between 1990 and 2017. Although improvements in indicators of sociodemographic development could 
explain some of these trends, changes in exposure to modifiable risk factors are related to the rates of decline in LRI 
mortality. No single intervention would universally accelerate reductions in health loss associated with LRIs in all 
settings, but emphasising the most dominant risk factors, particularly in countries with high case fatality, can 
contribute to the reduction of preventable deaths.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4·0 
license.
Introduction
Lower respiratory infections (LRIs) are the leading 
infectious cause of death among children younger than 
5 years globally, and mortality due to LRIs has declined 
substantially since the 1990s.1 Accelerating and main­
taining these declines is essential to meeting Sustainable 
Development Goals for under­5 childhood mortality and 
ensuring that children everywhere have the opportunity 
to live a full, healthy life. Yet, no country has a national 
pneumonia control strategy and pneu­ monia attracts a 
small fraction of international development assistance 
and research and development funding.2 Several global 
initiatives have sought to fill this gap and provide 
guidance on the most efficient interventions to avert 
illness and mortality and to champion LRI as a pre­
ventable cause of death.2–5 These programmes have 
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typically categorised risk factors and interventions into 
groups that are defined by the stage in the morbidity 
pathway at which they occur, including protection 
against illness, prevention of infection, and treatment of 
disease.4,5
The decline in under­5 LRI mortality has not been 
universal and has varied between countries.6 Under­
standing why it declined faster in some countries than 
in others provides specific, actionable evidence to 
further reduce disease burden. The Global Burden 
of Diseases, Injuries, and Risk Factors Study 2017 
(GBD 2017) is a systematic, scientific effort to quantify 
morbidity and mortality, including LRIs and their risk 
factors. We used results from GBD 2017 to assess which 
countries have performed best in reducing under­5 LRI 
mortality and compare countries on the basis of 
mortality rates, case fatality, and changes in risk factor 
exposure. This Article identifies countries where the 
change in under­5 LRI mortality has been largest, and 
uses the expansive set of estimates produced for 
GBD 2017 to analyse these changes, aiming to assess 
how and why they have occurred and to provide a 
roadmap for strategies to accelerate declines in 
mortality.
Methods
Overview
Detailed methods on GBD and on LRI estimation in 
GBD have been previously published.1,6–9 We describe 
these methods briefly. There were no substantial 
modelling changes between GBD 2016 and GBD 2017. 
LRIs are defined as diseases of the lower airways 
including pneumonia and bronchiolitis. Uncertainty in 
the LRI estimates are maintained through the modelling 
process using draws and is reflected as 2·5th and 
97·5th percentiles of the posterior distribution. In 
compliance with the Guidelines for Accurate and 
Transparent Health Estimates Reporting, data and code 
for GBD 2017 are publicly available. There are four 
main components of the analysis that we share here: 
LRI mortality estimation; LRI morbidity estimation; 
estimation of LRI mortality attributable to the inde­ 
pendent effects of risk factors; and an analysis of trends 
in LRI mortality.
LRI mortality and morbidity estimation
Most causes of death in GBD 2017, including LRI, are 
modelled with the Cause of Death Ensemble model 
tool.1,10 This statistical tool is designed to create a wide 
For the Guidelines for Accurate 
and Transparent Health 
Estimates Reporting see http://
gather-statement.org/
For the data and code for GBD 
2017 see https://ghdx.
healthdata.org/
Research in Context
Evidence before this study
Lower respiratory infections (LRIs) haven previously been 
identified as the leading infectious cause of death among 
children younger than 5 years. Several prominent global burden 
estimation groups, the WHO Maternal and Child Epidemiology 
Estimation group, and the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) have iteratively quantified the 
morbidity and mortality associated with LRIs. Based on these 
findings, several initiatives have sought to give guidance about 
effective ways to reduce health loss due to LRIs, including the 
Global Action Plan for Pneumonia and Diarrhoea, The Missing 
Piece, and a 2013 Lancet Series about effective ways to reduce 
child mortality. We have previously published estimates of 
LRI mortality from GBD 2015 and 2016 and in those Articles, 
have looked at risks and interventions. We conducted a search 
in PubMed on April 30, 2019, using the search terms “(“lower 
respiratory infection” OR pneumonia) AND mortality AND 
global AND risk AND trend*)”. After removing publications 
using GBD results, we found 49 articles, many of which 
reported on single risk factors or countries. These manuscripts 
have been primarily cross-sectional and, to our knowledge, 
no other study has attempted to evaluate changes in LRI 
disease burden over time due to demographic changes and 
changes in risk factor exposure.
Added value of this study
Here we report findings from GBD 2017, which builds on 
previous iterations of GBD with additional data and modelling 
improvements. We use estimates for 13 risk factors or 
interventions for LRI morbidity or mortality, produced for GBD, 
to evaluate changes in LRI mortality among children younger 
than 5 years. We use a conceptual framework to group these 
risk factors into categories of those that primarily prevent initial 
LRI episodes (such as the pneumococcal conjugate vaccine) 
and those that primarily protect children with LRIs from dying 
(such as antibiotic therapy). A major component of GBD is 
producing internally consistent and externally comparable 
estimates for all locations and over time, which allows us to 
identify countries where the incidence or mortality has changed 
most rapidly and to evaluate the risk factors or interventions 
are most associated with these changes. We provide 
cross-sectional and longitudinal estimates of the reasons for 
which children are dying from LRIs, how this varies, and where 
specific interventions might have the greatest impact.
Implications of all the available evidence
The incidence and mortality due to LRIs among HIV-negative 
children younger than 5 years has declined in many parts of the 
world, particularly because of decreased exposure to household 
air pollution, reductions in prevalence of childhood wasting, 
and increased vaccine coverage. However, there is variation by 
country, suggesting that there is no single intervention that will 
substantially reduce LRI mortality in every country. Individual 
countries or regions must consider their specific context to 
identify strategies to reduce LRI disease burden. Our results, 
while being mindful of the limitations of modelled estimates, 
can help provide the evidence needed to develop plans to give 
children everywhere a chance at a life free from LRIs.
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variety of models using a covariate selection algorithm 
and then to weight these models on the basis of their out­
of­sample predictive validity. We combined these models 
into an ensemble that predicts LRI mortality by age, 
sex, year, and location from 1980 to 2017. The model for 
LRI used vital registration data, demographic surveillance 
data, and verbal autopsy data. Covariates included 
childhood growth failure, ambient and household air 
pollution, nutritional deficiency, Socio­Demographic 
Index (SDI), and maternal education, among others 
(appendix pp 6). Causes of death in the GBD study are 
mutually exclusive and each death has one cause. 
Importantly, any LRI death among people with HIV is 
considered to have HIV as the underlying cause of death, 
therefore our results represent LRI mortality among HIV­
negative children younger than 5 years (appendix p 2).
The incidence and prevalence of LRI were modelled 
using DisMod­MR 2.1 (DisMod), a Bayesian meta­
regression tool.7 One of the primary advantages of 
DisMod is that it enforces consistency between incidence, 
prevalence, recovery, and mortality by solving a series of 
ordinary differential equations. Input data for this model 
are from population­representative surveys, health­care 
utilisation records, and scientific literature. We used 
two covariates to help predict in areas with little or no 
data coverage: a composite indicator of the cumulative 
risk exposure for LRI, called the summary exposure 
variable and developed for GBD, and the SDI 
(appendix pp 9, 10).
LRI trend analysis
We applied the results of the aforementioned models to 
spatiotemporal patterns. We compared estimates of LRI 
mortality and incidence in 1990 and 2017. To group 
countries into categories of similar burden, we identified 
country groupings on the basis of the burden in 1990. We 
split countries into four groups on the basis of the 
median mortality rate and incidence in 1990 and defined 
them as: high mortality and high incidence, high 
mortality and low incidence, low mortality and high 
incidence, and low mortality and low incidence.
Case fatality ratio
The case fatality ratio is defined as the ratio of number of 
deaths to number of incident cases. We fit a log­normal 
regression using SDI to predict the expected change in 
LRI case fatality ratio. This was considered the baseline 
change in case fatality ratio that is explained by SDI.
Risk factor attribution
Risk factors in GBD 2017 are causally related to LRI 
incidence or mortality.8 In this study, we analysed 13 of 
the risk factors for LRI identified in GBD 2017 (ambient 
air pollution, household air pollution, low Haemophilus 
influenzae type b [Hib] vaccine coverage, low 
pneu mococcal conjugate vaccine [PCV] coverage, no 
handwashing, second­hand smoking, zinc deficiency, 
breastfeeding, low antibiotic coverage, low birthweight 
and short gestation, stunting, underweight, and wasting; 
appendix pp 13–15). The estimation strategy for risk 
factors involved a counterfactual approach that quantifies 
the level of exposure to the risk factor in a population and 
the relative risk of LRI given exposure. Typically, the 
exposure in a population is modelled on the basis of 
surveys and scientific literature and the risk of LRI 
is derived from published meta­analyses. Childhood 
growth failure risks were estimated as a continuous 
exposure of the height or weight Z scores. Likewise, air 
pollution was considered a continuous exposure of the 
amount of fine particulate matter smaller than 2·5 μm in 
diameter. Other risk factors, such as low vaccine coverage, 
are modelled when the exposure is a population 
prevalence of being exposed to that risk factor (eg, the 
population prevalence of being unvaccinated for low 
vaccine coverage). Descriptions of the risk­factor exposure 
models and relative risks are provided in the 
appendix (pp 13–66). Risk factors in GBD are part of 
a comparative risk assessment framework and are 
modelled independently.8 Therefore, in our study, the 
burden associated with each risk factor can be considered 
as the LRI mortality that could be averted if exposure 
to that risk factor was eliminated. Since they were 
modelled independently, our analysis does not quantify 
the potential impact of combined interventions and 
combining risk­factor burden by summing risk factors is 
not appropriate and could lead to greater attribution than 
disease burden.
Intervention efficiency assessment
To assess the efficiency of targeted interventions for each 
risk factor among children younger than 5 years, we took 
advantage of the counterfactual definition of risk­factor 
burden such that the LRI mortality rate attributable to 
each risk factor was equivalent to the reduction expected 
given complete absence of the risk factor.8 For example, for 
vaccines, the risk exposure was defined as no vaccination, 
so the counterfactual was full vaccine coverage.
We classified risk factors into two categories based on 
their biological mechanism of risk and modelled after a 
conceptualisation proposed by the Global Action Plan 
for the Prevention and Control of Pneumonia and 
Diarrhoea.3 Conceptually, prevention risks are those 
that increase the probability of developing a LRI and 
include ambient air pollution, household air pollution, 
low Hib vaccine coverage, low PCV coverage, no access 
to a handwashing station with soap and water, 
second­hand smoke exposure, and zinc deficiency 
(appendix p 12). Protection risks are those that increase 
the probability of dying once a child developed 
an LRI and include suboptimal breastfeeding, low 
antibiotic coverage, low birthweight and short gestation, 
childhood stunting, childhood underweight, and child­
hood wasting (appendix p 13–15). We decomposed the 
effect of the change in exposure to each risk factor on 
See Online for appendix
For input data see https://
vizhub.healthdata.org/epi/
For data used in the model 
for LRI see http://ghdx.
healthdata.org/gbd-2017 and 
https://vizhub.healthdata.org/
cod/
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the LRI mortality rate between 1990 and 2017, 
accounting for the independent effects of population 
growth, population ageing, and other drivers of LRI 
mortality. This process has been described in detail 
elsewhere.6,8
Role of the funding source
The funder of the study played no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All collaborators had full access to 
all the data in the study and the corresponding author 
Deaths (95% UI) Mortality rate 
per 100 000 
(95% UI)
Percentage 
change 
mortality rate 
(95% UI), 
1990–2017
Incidence per 100 000 
(95% UI)
Percentage 
incidence 
change 
(95% UI), 
1990–2017
Case fatality 
ratio 
(95% UI)
Attributable 
fraction for 
all risks 
(95% UI)
Attributable 
fraction for 
prevention-
associated 
risks (95% UI)
Attributable 
fraction for 
protection-
associated 
risks (95% UI)
Global 808 920 
(747 286 to 873 591)
118·9 
(109·8 to 128·3)
–67·2% 
(–70·2 to –63·6)
12 197·8 
(9 762·1 to 14 908·7)
–32·4% 
(–37·5 to –27·2)
1·0% 
(0·9 to 1·1)
93·4% 
(90·3 to 95·7)
65·2% 
(50·2 to 77·6)
82·0% 
(62·6 to 92·1)
Central 
Europe, 
eastern 
Europe, and 
central Asia
16 040 
(14 296 to 18 051)
57·3 
(51·0 to 64·4)
–66·8% 
(–70·7 to –62·3)
9 219·6 
(7 103·3 to 11 586·8)
–36·3% 
(–43·2 to –28·6)
0·6% 
(0·6 to 0·7)
84·5% 
(77·5 to 89·7)
47·8% 
(33·5 to 62·2)
75·8% 
(53·6 to 88·4)
Central Asia 13 937 
(12 246 to 15 922)
145·4 
(127·7 to 166·1)
–69·9% 
(–73·8 to –65·2)
6 206·9 
(5 003·0 to 7 601·2)
–46·9% 
(–53·8 to –39·2)
2·3% 
(2·2 to 2·6)
85·1% 
(78·1 to 90·1)
47·5% 
(32·6 to 62·2)
77·2% 
(54·6 to 89·5)
Central Europe 707 
(632 to 795)
12·5 
(11·2 to 14·1)
–84·2% 
(–86·1 to –82·1)
8 700·5 
(6 862·8 to 10 868·4)
–26·9% 
(–34·5 to –18·2)
0·1% 
(0·1 to 0·2)
80·5% 
(71·7 to 87·6)
53·0% 
(39·9 to 66·1)
71·4% 
(47·0 to 85·5)
Eastern Europe 1 396 
(1 277 to 1 509)
10·9 
(10·0 to 11·8)
–78·2% 
(–80·2 to –76·5)
11 710·4 
(8 712·6 to 15 012·1)
–32·5% 
(–41·5 to –23·2)
0·1% 
(0·1 to 0·1)
81·2% 
(72·5 to 87·8)
49·0% 
(34·2 to 63·1)
72·6% 
(50·7 to 85·1)
High income 1 857 
(1 702 to 2 027)
3·2 
(2·9 to 3·5)
–70·6% 
(–73·2 to –67·9)
4 843·7 
(3 772·5 to 6 137·4)
–19·5% 
(–24·9 to –13·4)
0·1% 
(0·1 to 0·1)
67·7% 
(55·8 to 78·1)
28·8% 
(16·0 to 44·7)
66·5% 
(42·0 to 82·1)
Australasia 42 
(32 to 53)
2·3 
(1·8 to 2·9)
–65·4% 
(–76·2 to –53·4)
5 798·0 
(4 448·5 to 7 449·4)
2·2% 
(–6·7 to 11·5)
0·0% 
(0·0 to 0·0)
66·6% 
(53·8 to 78·1)
23·0% 
(10·1 to 41·9)
65·8% 
(40·8 to 82·1)
High-income 
Asia Pacific
180 
(163 to 197)
2·4 
(2·2 to 2·6)
–72·2% 
(–75·9 to –68·4)
8 472·0 
(6 595·5 to 10 872·2)
–3·9% 
(–14·8 to 8·2)
0·0% 
(0·0 to 0·0)
75·3% 
(63·3 to 84·6)
33·3% 
(20·9 to 48·9)
70·5% 
(43·5 to 85·9)
High-income 
North America
684 
(618 to 742)
3·2 
(2·9 to 3·5)
–60·6% 
(–65·9 to –56·2)
4 791·2 
(3 679·0 to 6 155·8)
–29·6% 
(–33·9 to –25·3)
0·1% 
(0·1 to 0·1)
57·1% 
(43·7 to 70·2)
21·0% 
(9·1 to 37·6)
61·0% 
(36·9 to 78·4)
Southern Latin 
America
568 
(466 to 696)
11·1 
(9·1 to 13·6)
–77·5% 
(–82·0 to –72·3)
11 895·3 
(9 444·5 to 14 789·3)
–11·2% 
(–23·8 to 2·8)
0·1% 
(0·1 to 0·1)
78·3% 
(67·7 to 86·7)
37·1% 
(19·7 to 56·4)
73·2% 
(48·2 to 87·0)
Western 
Europe
383 
(350 to 426)
1·7 
(1·6 to 1·9)
–72·0% 
(–75·6 to –68·8)
1 940·4 
(1 526·6 to 2 431·0)
–19·1% 
(–24·6 to –13·2)
0·1% 
(0·1 to 0·1)
67·4% 
(55·2 to 78·1)
28·1% 
(16·0 to 43·6)
64·5% 
(40·9 to 80·1)
Latin America 
and Caribbean
21 606 
(19 618 to 24 079)
42·4 
(38·5 to 47·3)
–79·1% 
(–81·9 to –75·8)
12 192·4 
(9 920·3 to 14 782·1)
–37·4% 
(–42·4 to –31·9)
0·3% 
(0·3 to 0·4)
78·8% 
(70·5 to 85·9)
44·5% 
(30·5 to 58·4)
72·4% 
(45·9 to 87·8)
Andean Latin 
America
3 787 
(2 988 to 4 694)
56·5 
(44·6 to 70·0)
–87·0% 
(–90·0 to –83·3)
16 610·1 
(14 120·4 to 19 324·6)
–40·3% 
(–46·5 to –33·0)
0·3% 
(0·3 to 0·4)
74·7% 
(64·8 to 83·0)
40·0% 
(23·0 to 57·9)
68·6% 
(40·4 to 86·2)
Caribbean 3 932 
(2 985 to 5 131)
100·5 
(76·3 to 131·2)
–51·8% 
(–63·9 to –35·7)
11 164·6 
(8 986·4 to 13 596·2)
–9·9% 
(–18·2 to 0·5)
0·9% 
(0·8 to 1·0)
89·3% 
(84·1 to 93·2)
68·9% 
(53·4 to 81·9)
76·7% 
(52·9 to 90·1)
Central Latin 
America
9 257 
(8 062 to 10 826)
38·3 
(33·3 to 44·7)
–73·6% 
(–77·4 to –68·5)
15 259·9 
(12 336·1 to 18 680·2)
–39·9% 
(–45·4 to –33·9)
0·3% 
(0·2 to 0·3)
78·9% 
(70·7 to 85·6)
41·8% 
(26·9 to 56·8)
72·5% 
(45·2 to 88·0)
Tropical Latin 
America
4 630 
(4 163 to 5 158)
28·8 
(25·9 to 32·0)
–85·8% 
(–88·6 to –83·7)
5 990·7 
(4 896·3 to 7 296·4)
–45·2% 
(–49·3 to –40·9)
0·5% 
(0·4 to 0·5)
73·2% 
(62·3 to 82·7)
28·0% 
(17·2 to 41·5)
70·6% 
(41·9 to 87·4)
North Africa 
and Middle 
East
43 558 
(37 550 to 49 735)
67·7 
(58·3 to 77·3)
–76·5% 
(–80·7 to –71·1)
19 258·4 
(15 414·9 to 23 501·0)
–25·6% 
(–32·2 to –19·0)
0·4% 
(0·3 to 0·4)
91·9% 
(87·6 to 94·9)
62·3% 
(46·8 to 75·6)
81·1% 
(58·5 to 92·3)
South Asia 249 595 
(225 643 to 275 313)
143·1 
(129·4 to 157·9)
–71·2% 
(–74·9 to –66·7)
13 153·1 
(10 465·5 to 16 238·0)
–22·7% 
(–28·7 to –16·2)
1·1% 
(1·0 to 1·2)
95·9% 
(93·9 to 97·4)
65·4% 
(50·5 to 77·3)
83·2% 
(66·8 to 92·1)
Southeast 
Asia, east 
Asia, and 
Oceania
63 661 
(58 190 to 69 821)
45·0 
(41·1 to 49·3)
–85·7% 
(–87·2 to –83·7)
13 383·7 
(10 686·7 to 16 401·7)
–38·8% 
(–44·3 to –32·3)
0·3% 
(0·3 to 0·4)
88·7% 
(83·6 to 92·8)
61·2% 
(45·3 to 75·0)
78·8% 
(56·2 to 90·8)
East Asia 22 824 
(20 743 to 25 438)
27·1 
(24·6 to 30·2)
–90·7% 
(–91·9 to –89·2)
9 376·4 
(7 387·3 to 11 625·0)
–54·8% 
(–59·6 to –49·2)
0·3% 
(0·3 to 0·3)
83·2% 
(76·5 to 88·9)
61·5% 
(41·9 to 77·8)
70·9% 
(46·3 to 85·7)
Oceania 1 770 
(1 295 to 2 325)
99·5 
(72·8 to 130·7)
–48·1% 
(–63·1 to –26·9)
16 573·7 
(13 249·1 to 20 596·4)
–12·5% 
(–22·0 to –1·8)
0·6% 
(0·5 to 0·6)
93·1% 
(89·9 to 95·6)
68·3% 
(50·0 to 82·7)
85·2% 
(64·2 to 94·7)
Southeast Asia 39 066 
(34 532 to 44 291)
70·2 
(62·1 to 79·6)
–80·7% 
(–83·5 to –77·1)
19 344·3 
(15 535·4 to 23 655·9)
–20·7% 
(–27·5 to –13·0)
0·4% 
(0·3 to 0·4)
91·7% 
(87·5 to 94·8)
61·2% 
(46·0 to 74·3)
82·6% 
(61·1 to 93·1)
(Table continues on next page)
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had final responsibility for the decision to submit for 
publication.
Results
Globally, LRIs were the leading infectious cause of 
death among children younger than 5 years in 2017 
(808 920 deaths, 95% uncertainty interval [UI] 
747 286–873 591; table), responsible for 15·0% (14·0–16·0) 
of all under­5 deaths. There was no substantial difference 
in the under­5 LRI mortality rate between boys 
(118·2 deaths, 108·2–129·6, per 100 000 boys) and girls 
(119·5 deaths, 109·6–129·6, per 100 000 girls; data are 
available on GBD­Compare). Since 1990, there has been a 
substantial decrease in the number of deaths 
(65·4% decrease, 61·5–68·5; from 2 337 538 deaths to 
808 920 deaths), the mortality rate (67·2% decrease, 
63·6–70·2; from 362·7 deaths, 330·1–392·0, per 
100 000 children to 118·9 deaths, 109·8–128·3, per 
100 000 children; table), and the percent of under­5 deaths 
that were due to LRIs (24·6% decrease, 17·2–30·4; from 
19·9%, 18·1–21·4, to 15·0%, 14·0–16·0) among children 
younger than 5 years.
Most under­5 LRI deaths in 2017 occurred in 
India (185 429 deaths, 95% UI 167 676–204 328), 
Nigeria (153 069 deaths, 115 332–196 193), and Pakistan 
(40 480 deaths, 28 805–57 002; appendix pp 67–92). The 
highest LRI mortality rate occurred in South Sudan 
(527·7 deaths, 386·2–707·5, per 100 000 children; 
figures 1, 2A; appendix pp 67–92). Likewise, reductions in 
LRI mortality rates have varied by location: Turkey (96·4% 
decline, 94·4–97·6) declined at the fastest rate whereas 
Niger experienced the largest absolute reduction in 
under­5 LRI mortality rate, from the highest mortality 
rate globally in 1990 (1349·0 deaths, 1027·0–1714·3, per 
100 000 children) to 329·7 deaths (231·0–451·6) per 
100 000 children in 2017 (ie, 1019·3 fewer deaths, 
796·0–1262·7, per 100 000 children; figures 1, 2C; 
appendix pp 67–92). Between 1990 and 2005, the fastest 
annualised rate of change in LRI mortality rate occurred 
in Oman (14·9% decrease per year) and the fastest 
annualised rate of change between 2000 and 2017 
occurred in Saudi Arabia (12·7% decrease per year; data 
not shown, available on GBD­Compare).
The global LRI incidence among children younger than 
5 years was 12 197·8 new cases (95% UI 9762·1–14 908·7) 
per 100 000 child­years. LRI incidence was highest in 
Guatemala (27 126·3 new cases, 22 443·4–32 304·3, per 
100 000 child­years; figure 1B, 2B; appendix pp 67–92). 
LRI incidence declined globally (from 18 054·0 new cases, 
14 808·2–21 833·2, per 100 000 child­years, in 1990; 
32·4% decrease, 27·2–37·5) with the fastest declines in 
Turkmenistan (58·0% decrease, 50·9–64·5), Mongolia 
(56·6% decrease, 48·9–63·9), and China (56·0% decrease, 
50·5–60·6; figure 1; appendix pp 67–92). However, the 
incidence of LRI increased in some locations such as 
Norway (58·9% increase, 44·4–75·1; from 3406·1 new 
cases, 2659·4–4294·7, per 100 000 child­years to 5411·7 new 
cases, 4115·6–7016·1, per 100 000 child­years) and Lebanon 
(40·8% increase, 21·0–59·1; from 15 400·6 new cases, 
12 300·8–19 254·4, per 100 000 child­years to 21 680·6 new 
cases, 16 166·6–28 291·3, per 100 000 child­years; figures 1, 
2D; appendix pp 67–92). Additional results by age, sex, 
location, and year from 1990 to 2017 are available on 
GBD­Compare.
The global case fatality ratio for LRIs decreased from 
2·0% (2·2–1·8) in 1990, to 1·0% (95% UI 0·9 to 1·1) in 
2017. In 2017, the lowest case fatality ratios globally 
occurred in Saudi Arabia (<0·1%, <0·1 to <0·1) and 
For GBD-Compare see https://
vizhub.healthdata.org/gbd-
compare/ and http://ihmeuw.
org/4wwe
Deaths (95% UI) Mortality rate 
per 100 000 
(95% UI)
Percentage 
change 
mortality rate 
(95% UI), 
1990–2017
Incidence per 100 000 
(95% UI)
Percentage 
incidence 
change 
(95% UI), 
1990–2017
Case fatality 
ratio 
(95% UI)
Attributable 
fraction for 
all risks 
(95% UI)
Attributable 
fraction for 
prevention-
associated 
risks (95% UI)
Attributable 
fraction for 
protection-
associated 
risks (95% UI)
(Continued from previous page)
Sub-Saharan 
Africa
412 604 
(357 299 to 471 442)
252·5 
(218·7 to 288·6)
–62·9% 
(–67·6 to –56·8)
10 493·2 
(8 558·0 to 12 858·7)
–34·5% 
(–39·0 to –29·4)
2·4% 
(2·2 to 2·6)
94·0% 
(90·9 to 96·2)
68·0% 
(50·6 to 81·8)
82·8% 
(61·9 to 93·2)
Central 
sub-Saharan 
Africa
47 357 
(37 232 to 58 184)
239·7 
(188·4 to 294·5)
–61·8% 
(–69·9 to –51·0)
11 728·4 
(9 490·0 to 14 347·2)
–28·4% 
(–36·3 to –19·7)
2·0% 
(2·0 to 2·1)
94·2% 
(91·0 to 96·4)
68·5% 
(48·8 to 83·9)
82·9% 
(58·6 to 94·3)
Eastern 
sub-Saharan 
Africa
111 613 
(99 529 to 124 670)
176·3 
(157·2 to 196·9)
–71·2% 
(–75·4 to –65·6)
12 894·4 
(10 363·6 to 15 813·8)
–33·7% 
(–38·7 to –28·6)
1·4% 
(1·2 to 1·5)
93·3% 
(90·0 to 95·7)
66·7% 
(51·4 to 78·4)
81·3% 
(59·0 to 92·6)
Southern 
sub-Saharan 
Africa
10 513 
(9 192 to 12 063)
123·1 
(107·7 to 141·3)
–54·7% 
(–61·5 to –46·6)
7 357·1 
(6 032·7 to 8 847·9)
–30·3% 
(–35·5 to –24·5)
1·7% 
(1·6 to 1·8)
87·4% 
(81·5 to 92·1)
51·9% 
(36·5 to 66·3)
77·0% 
(51·0 to 90·7)
Western 
sub-Saharan 
Africa
243 122 
(198 471 to 290 155)
338·7 
(276·5 to 404·3)
–60·2% 
(–67·1 to –50·7)
8 408·3 
(6 875·4 to 10 219·7)
–37·7% 
(–42·7 to –31·7)
4·0% 
(4·0 to 4·0)
94·5% 
(91·7 to 96·5)
69·3% 
(49·0 to 84·9)
83·8% 
(63·7 to 93·8)
Estimates for every country are available in the appendix (pp 67–92). UI=uncertainty interval.
Table: Deaths and case fatality attributable to and incidence of lower respiratory infections among children younger than 5 years by Global Burden of Diseases, Injuries, and Risk Factors 
Study regions and super-regions, 2017
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Slovenia (<0·1%, <0·1 to <0·1), whereas the highest 
occurred in Nigeria (5·8%, 5·4 to 6·0) and Tajikistan 
(4·2%, 4·2 to 4·3; figure 3; appendix pp 67–92). In 2017, 
if all countries with a case fatality ratio exceeding the 
global average had been reduced to the global average, 
then 291 611 deaths would be averted. Some countries in 
central Asia (eg, Azerbaijan, Mongolia, and Tajikistan) 
and in western sub­Saharan Africa (eg, Guinea, Nigeria, 
and Sierra Leone) had case fatality ratios much higher 
than expected on the basis of SDI alone (figure 3). If 
these countries had experienced case fatality ratios 
corresponding with the average relationship between 
case fatality ratio and SDI, an additional 326 900 deaths, 
including 133 600 in Nigeria, could possibly have been 
averted in 2017.
Overall, 93·4% (95% UI 90·3 to 95·7) of under­5 LRI 
mortality could be attributed to risk factors and 
interventions modelled by GBD in 2017 (table). Because 
of the counterfactual strategy in risk factor attribution, 
this suggests that 755 513 under­5 LRI deaths 
(691 459 to 819 746) would have been avertable if 
exposures to all risk factors had been reduced to their 
theoretical minimum levels. Risk factors in the GBD 
study are not mutually exclusive and so individual 
attributable fractions might sum to more than 100%. 
Protection­related risk factors were responsible for 
82·0% (62·6 to 92·1) of under­5 LRI deaths in 2017 
(table), including 52·6% (35·1 to 62·8) of under­5 LRI 
deaths attributable to wasting, 14·7% (1·6 to 34·7) to 
stunting, 11·5% (7·6 to 20·4) to underweight, and 7·4% 
(4·2 to 11·1) to non­exclusive breastfeeding (data available 
on GBD­Compare). Interventions to prevent risk 
exposure could have averted 65·2% (50·2 to 77·6) of 
under­5 LRI deaths in 2017 (table) including 11·2% 
(7·3 to 14·8) of deaths attributable to insufficient 
handwashing with soap, 28·5% (22·4 to 34·1) to 
household air pollution, 17·5% (13·2 to 22·6) to ambient 
particulate matter pollution, 19·2% (16·5 to 21·8) to low 
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PCV coverage, and 9·6% (<0·1 to 20·6) due to low Hib 
vaccine coverage (data available on GBD­Compare).
At the global level, changes to all risk factors for LRI 
mortality accounted for a 12·2% decrease (95% UI 
11·6–13·1) between 1990 and 2017 (figure 4; appendix pp 
93–111). Globally, increased Hib vaccine coverage (11·4%, 
0·0–24·5) and PCV coverage (6·3%, 6·1–6·3) were 
responsible for large decreases in LRI mortality among 
children younger than 5 years between 1990 and 2017 
(figure 4; appendix pp 93–111). This effect was evident 
also in all subgroups of countries classified according to 
their mortality and incidence rates in 1990. Although 
decreased exposure to household air pollution reduced 
LRI mortality by 8·4% (6·8–9·2), increased exposure 
to ambient air pollution increased mortality by 4·1% 
(2·7–6·2; figure 4).
In 1990, both the mortality and incidence rates were 
higher than the corresponding country­group mean 
values in 68 countries, which were categorised as high 
mortality and high incidence (upper right quadrant of 
figure 1A; figure 4A). From 1990 to 2017, the under­5 LRI 
mortality rate declined by a greater amount than the 
global median in 50 (74%) of these 68 countries and the 
LRI mortality rate decreased by a mean of 398·0 deaths 
(95% UI 100·7–857·8) per 100 000 children in these 
countries (figures 1, 4A). These countries tended to have 
large decreases in LRI mortality attributable to changes 
in childhood growth failure indicators, including a mean 
12·7% (2·3–31·2) reduction due to childhood wasting, 
5·5% (1·5–9·5) reduction due to childhood stunting, 
and 5·1% (1·6–10·2) reduction due to childhood 
underweight (figure 4A). Among the countries with the 
Figure 1: Under-5 LRI incidence and mortality rates in 1990 (A) and 2017 (B)
Points represent countries (labelled according to the International Organization for Standardization 3166 alpha-3 codes) and the colour indicates the Global Burden 
of Diseases, Injuries, and Risk Factors Study super-region each of them belongs to. The vertical line indicates the median incidence among all countries and the 
horizontal line indicates the median mortality rate among all countries. The plots are therefore divided into four quadrants based on each country’s relative incidence 
and mortality rate compared with all other countries in 1990 and in 2007.
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(Figure 2 continues on the next page)
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Figure 2: Global distribution of LRI burden among children younger than 5 years
(A) Under-5 LRI mortality rate in 2017; (B) LRI incidence per 100 000 child-years in 2017; (C) absolute difference in LRI mortality rate between 1990 and 2017; and (D) absolute difference in LRI 
incidence rate between 1990 and 2017. ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. LRI=lower respiratory infection. TLS=Timor-Leste. TTO=Trinidad 
and Tobago. VCT=Saint Vincent and the Grenadines.
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greatest magnitude change, childhood stunting 
accounted for a 14·3% (2·5–28·9) decrease in LRI 
mortality rate in Equatorial Guinea and a 10·6% 
(2·0–22·8) decrease in Uganda. Childhood underweight 
accounted for an 11·9% (7·5–19·7) decrease in LRI 
mortality rate in Timor­Leste and a 10·6% (6·8–18·0) 
decrease in Angola. Changes in childhood wasting were 
responsible for a 42·6% (26·3–55·3) decrease in LRI 
mortality rate in Guatemala and a 37·2% (29·0–42·2) 
decrease in Laos (figure 4A). The greatest absolute 
decline in LRI mortality rate occurred in Niger and the 
vaccine­related risk factors were responsible for the 
largest decrease in LRI mortality (18·2% [0·0–37·3] 
decrease due to increased Hib vaccine coverage and 
19·8% [18·6–20·0] decrease due to increased PCV 
coverage). Some countries in this group had large 
reductions in LRI mortality due to household air 
pollution (27·6% [20·4–33·3] reduction in Angola) and 
vaccine coverage (23·5% [0·0–51·0] decline due to 
increased Hib vaccine coverage and 27·2% [23·0–30·5] 
decline due to increased PCV coverage in Burundi). The 
LRI mortality rate increased due to ambient air pollution 
in 64 (94%) of 68 countries in this group (median 
increase 3·4% [0·0–9·5]; figure 4A; appendix pp 93–111).
In 29 countries, the mortality rate was higher than the 
global median but the incidence was lower than the global 
median in 1990. We classified these countries as having 
high mortality and low incidence (upper left quadrant of 
figure 1; figure 4B). This group of countries had a mean 
decline in LRI mortality rate of 245·0 deaths (44·7–514·6) 
per 100 000 children during 1990–2017. Countries in this 
group tended to have large reductions in LRI mortality 
attributable to changes in household air pollution (mean 
decrease 13·1% [5·6–21·5]), including a 24·6% (17·9–30·6) 
decline in Swaziland (eSwatini). Increased Hib vaccine 
coverage also contributed to a substantial reduction in LRI 
mortality in this group of countries (16·0% decrease 
[10·0–23·8]). This group also had small declines in 
LRI mortality attributable to improved breastfeeding 
(mean 1·0% [0·0–2·2]) and zinc deficiency (mean 0·6% 
[0·2–2·3]). The LRI mortality rate decreased by 
662·2 deaths (554·7–755·6) per 100 000 children in 
Nigeria, where the largest attributable changes were due to 
household air pollution (18·3% decrease [11·9–22·9]), 
childhood wasting (9·9% decrease [8·5–11·1]), and 
childhood stunting (6·4% decrease [1·4–13·5]; 
figure 4B; appendix pp 93–111).
In 29 countries, the mortality rate was lower than the 
global median in 1990 but the incidence was higher than 
the global median. We classified these countries as having 
low mortality and high incidence (lower right quadrant of 
figure 1; figure 4C). The LRI mortality rate decreased by 
45·9 deaths (95% UI 7·8–90·4) per 100 000 children in 
these countries and the absolute change in the LRI 
mortality rate was in the 3rd quintile for 18 (62%) of 
29 countries. Relative to other groups, this group of 
countries had greater reductions attributable to behavioural 
risk factors such as no handwashing (1·0% mean decline 
[0·2–3·0]), second­hand smoke exposure (2·2% mean 
decline [0·3–3·7]), and childhood wasting (10·3% mean 
decline [2·3–22·2]). Although vaccine coverage reduced 
LRI mortality in this country group, this reduction was 
similar to the all­country mean for Hib vaccine coverage 
(13·9% mean reduction [5·2–22·8]) and slower than the 
all­country mean for PCV coverage (9·0% mean reduction 
[6·4–24·6]). By contrast, these countries had mean 
increases in LRI mortality attributable to low antibiotic 
coverage (2·6% median increase [1·1–4·8]) and low 
birthweight and short gestation (2·6% median increase 
[0·1–5·7]). Many of these countries did not introduce the 
PCV, which was responsible for an increase in LRI 
mortality in ten countries (figure 4C), with Jordan 
(11·0% increase [6·2–15·9]) and Ukraine (6·7% increase 
[3·8–9·8]) having the largest increase in mortality rate due 
to low PCV coverage (appendix pp 93–111).
In 69 countries, both mortality and incidence were 
lower than the global median in 1990. We classified these 
countries as having low mortality and low incidence 
(lower left quadrant of figure 1; figure 4D). The mean 
Figure 3: Case fatality ratio among children under-5 in 2017
We used the Socio-demographic Index as a predictor of the case fatality ratio by country. The solid black line 
indicates a log-linear curve for these values.
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decline in LRI mortality rate in these countries was 
13·7 deaths (95% UI 1·7 to 39·9) per 100 000 children. 
Many of these countries reduced exposure to ambient air 
pollution (the greatest reduction was a 3·5% decline, 
2·5 to 3·8, in the Czech Republic). The mean decline due 
to second­hand smoke exposure was 2·2% (–0·3 to 5·9) 
and was greatest in Greece (8·8% reduction, 7·3 to 10·9) 
and Iceland (7·5% reduction, 5·6 to 9·4; figure 4D). 
Countries in this group generally had decreases in LRI 
mortality attributable to greater vaccine coverage but 
these changes were similar to the decrease across all 
countries (appendix pp 93–111).
Figure 4: Change in LRI 
mortality rate attributable 
to changes in risk factor 
exposure by country, 
1990–2017
Countries are grouped by their 
mortality and incidence 
(higher or lower than the 
global median in 1990, as 
identified by the quandrants 
in figure 1A) and are ordered 
within each group from 
slowest absolute change in 
under-5 LRI mortality rate 
per 1000 children between 
1990 and 2017. Colors indicate 
the quintile for the absolute 
change in each risk factor 
attributable fraction among all 
countries. Country groupings 
are: (A) high mortality, 
high incidence (n=68); 
(B) high mortality, low 
incidence (n=29); (C) low 
mortality, high incidence 
(n=29); and (D) low mortality, 
low incidence (n=69). 
Hib=Haemophilus influenzae 
type b. PCV=pneumococcal 
conjugate vaccine.
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Discussion
At the global level, LRI mortality declined substantially 
among children younger than 5 years between 
1990 and 2017. Despite these declines, such progress has 
not occurred equally across countries, and LRIs remained 
the leading infectious cause of death among children 
younger than 5 years in 2017. In most locations, 
LRI incidence declined more slowly than mortality, 
suggesting that improvements in protecting against 
death are probably outpacing improvements in reducing 
the underlying risk of infection. Although SDI is strongly 
associated with under­5 LRI mortality, changes in SDI 
were not strongly associated with changes in mortality 
rates between 1990 and 2017. At the global level, 93·4% of 
under­5 LRI deaths were attributable to a risk factor. 
Among risk factors estimated in GBD 2017, we have 
conceptualised the change in under­5 LRI burden into 
two components, the changes in risks that predispose 
children to disease (prevention risk factors) and those that 
increase the risk of mortality given disease (protection 
risk factors). These categories are likely to partly overlap. 
For example, childhood growth failure, via immunological 
mechanisms, might make children both more likely to 
get sick and die from an LRI. Such a distinction is broad 
but provides a conceptual framework with which to 
assess the relationship between trends in risk factor 
exposure, mortality, incidence, and case fatality.
One of the main findings from our study is that the 
drivers of change in LRI mortality are not universal and 
might be highly specific to each location and that 
strategies to reduce health loss due to LRI must be 
tailored to a given setting. For example, the three 
countries with the greatest absolute decline in LRI 
mortality rate were Niger (1019·3 fewer deaths per 
100 000 children), Laos (944·4 fewer deaths per 
100 000 children) and Afghanistan (919·0 fewer deaths 
per 100 000 children). The Hib and pneumococcal 
vaccines were responsible for the largest percent change 
in Niger, whereas changes in childhood wasting 
explained more than 20% of the decline in Laos and 
Afghanistan, and lower exposure to household air 
pollution in Afghanistan decreased LRI mortality rate by 
19·3%. By contrast, the two countries that observed the 
largest relative decline in LRI mortality between 
1990 and 2017, China and Turkey, had relatively small 
changes attributable to changes in risk factors. 
Under­5 LRI mortality in China decreased by 
91·2% between 1990 and 2017, whereas the mortality rate 
decreased by 26·2% because of changes in risk factor 
exposure. This suggests that other factors might explain 
the change in some countries.
Other studies have identified economic development, 
health­care reform to provide government­sponsored 
health care in rural areas,11,12 improved detection of 
pneumonia following the severe acute respiratory 
syndrome and influenza virus subtype H1N1 pandemics, 
and programmes to reduce household air pollution from 
solid fuels as the main drivers of reduction in LRI 
mortality in China.13 The decline in LRI mortality in China 
might also be related to a so­called nutritional transition—
similar to a transition previously observed in the USA and 
other high­income countries, but occurring at lower gross 
national product14—and might be explained by agricultural 
policies (including sub sidisation and subsequent increase 
in soya bean oil and soya consumption),15 urbanisation,16 
liberalisation of food production,15 and rapid economic 
development (exceeding 8% annually) in China during 
this time.17 This study did not include covariates that 
would specifically capture changes in infrastructure or 
food production but such changes might be reflected in 
the rapid increase in SDI observed in China between 
1990 and 2017, and these trends deserve further 
investigation. Interventions and structural policies that 
aim to improve childhood nutrition can play a substantial 
role in protecting children from dying because of 
infectious diseases, including LRIs.5
China and Turkey have some of the fastest 
improvements in the Healthcare Access and Quality 
Index, a composite metric of amenable mortality.18 This 
improvement in preventing amenable causes of death 
suggests that the health­care systems in these countries 
have improved and are likely to have contributed to the 
rapid declines in LRI mortality. Access to care, adherence 
to treatment protocols, maternal education, appropriate 
technology, and adequate health­care staffing have all 
been identified as predictors of under­5 LRI survival5 
that were not quantified in this study and might be 
components of a comprehensive LRI treatment strategy.
Our study found that low antibiotic use for LRIs was 
responsible for an increase in LRI mortality, particularly 
among countries with high mortality in 1990. An 
analysis of appropriate antibiotic therapy for child hood 
pneumonia determined that the availability and acces­
sibility of WHO­recommended antibiotics is not 
equitable in some locations with substantial variation 
within countries.19 Antibiotic use for symptoms of 
pneumonia varied greatly among low­income and 
middle­income countries,20 and was estimated at just 
18·8% globally, in 2017, in this study. A cohort study 
consisting of eight sites and a mixture of urban and rural 
locations found that 61% of children aged 0–2 years with 
acute LRI received antibiotics, including 69% in rural 
Tanzania and 86% in urban Bangladesh.21 Community 
case management of acute respiratory infections could 
reduce pneumonia­related mortality by 32%, according 
to a systematic review,22 and effective treatments such 
as oxygen therapy, rehydration, and antibiotics can 
dramatically reduce LRI mortality.
Appropriate care for LRIs might also depend on the 
availability and utilisation of health care. Primary health 
care in some low­income and middle­income countries 
has experienced challenges in funding, with general 
underuse of facilities and neglected human resources. 
Nigeria had the highest case fatality ratio globally in 2017 
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(5·7%, 95% UI 5·4–6·0) but had average coverage of 
antibiotics, suggesting other factors might be driving the 
high rate. Nigeria is a country of complex demographic, 
geographic, and cultural characteristics with substantial 
variation in health and health­care utilisation and 
performance indicators.23 It has the highest population of 
any country in Africa and by far the most deaths due to 
LRI among children younger than 5 years. Yet, a review of 
published literature on child health interventions found 
only 18 papers from Nigeria.24 Building evidence from 
high­burden countries should be a priority and is essential 
to a complete understanding of health loss due to LRI. 
One qualitative study25 revealed demand­side barriers to 
health­care utilisation in Nigeria, suggesting that costs, 
physical distance, cultural considerations, and knowledge 
of symptoms and warning signs might all play a role in 
delayed care­seeking and could explain behaviours in 
other locations. In one study26 of six countries in sub­
Saharan Africa, only 30% of care givers recognised fast 
breathing or difficulty in breathing as a symptom of LRI. 
Among several countries in western sub­Saharan Africa, 
the proportion of care givers who reported seeking 
treatment for symptoms of pneumonia ranged from 
27·4% in Chad to 73·2% in Sierra Leone and was 41·9% 
in Nigeria.26
Appropriate care and treatment to protect against LRI 
mortality are important but the two risk factors 
responsible for the largest reduction in LRI mortality at 
the global level and for the largest prevention of incident 
episodes of LRI are Hib vaccine coverage and household 
air pollution. Vaccines have been an important part of 
LRI prevention in many countries. In 2011, 2% of 
US$30·6 billion in international assistance for health 
spending was spent on pneumonia, and about 82% of 
that was through Gavi, the Vaccine Alliance, suggesting 
that nearly all pneumonia funding was for vaccines.27 
A different analysis found that between 2000 and 
2015, pneumonia received approximately $3 billion in 
funding for research and development, compared with 
more than $38 billion that went towards HIV/AIDS 
research during the same time.28 Of that $3 billion, 
about $839 million went to treatment, another 
$164 million to diagnostics, and $858 million went to 
vaccines.28
Globally, Hib and pneumococcal vaccines were 
responsible for an estimated 11·4% (Hib) and 6·3% (PCV) 
decrease in LRI mortality. Although nearly every country 
has introduced the Hib vaccine in their immunisation 
programmes, several high­burden countries such as 
Nigeria, Chad, and Somalia have not introduced the 
pneumococcal vaccine. Studies have shown substantial 
reductions in hospital admissions for pneumonia, 
invasive Hib, and pneumococcal pneumonia following 
vaccine introduction.29–32 Although more countries might 
introduce PCV with Gavi support, there is uncertainty 
regarding the sustainability of these vaccines among 
countries that approach graduation from Gavi.33 The 
continued and expanded use of these vaccines have 
substantial impacts on under­5 LRI mortality and 
should be prioritised as part of routine immunisation 
programmes to prevent these deaths.
Two other risk factors that are associated with preventing 
incident cases of LRI had opposite trends in burden 
attribution. Between 1990 and 2017, LRI mortality 
decreased by 8·4% globally due to reductions in household 
air pollution but increased by 4·1% due to ambient air 
pollution. A pair of systematic reviews and meta­analyses 
found that exposure to household air pollution from solid 
fuel use increased the risk of pneumonia among children 
younger than 5 years.34,35 A pair of randomised controlled 
trials found little statistical evidence of a reduction in 
pneumonia incidence with provision of chimneys36 or 
cleaner burning cookstoves,37 and several more studies 
investigating household air pollution and childhood 
pneumonia are in progress.38,39 This suggests that the 
provision of chimneys or cleaner burning practices does 
not result in a sufficient reduction of air pollution to 
translate into a reduction in health effects. This finding is 
consistent with the analysis and recommendations by the 
WHO guidelines. Rapid urbanisation in many countries 
and a shift from conventional heating sources, such as 
coal and wood, to natural gas have probably contributed 
to reduced exposure to household air pollution.40 
Reduced exposure to household air pollution was strongly 
associated with decreased incidence and mortality, 
particularly in high­burden countries in our study. We 
have previously described the interplay between develop­
ment and ambient air pollution that is occurring in many 
countries that are rapidly urbanising and growing 
economically.6 Preventing LRI cases and deaths should be 
a part of any policy conversation regarding the burning of 
fossil fuels, and focusing on health effects of carbon­based 
energy might be a powerful rhetorical tool in developing 
policy to reduce air pollution.41–43
There are several limitations in this study. We have 
previously described some of the data gaps associated 
with LRI mortality modelling, specifically among 
countries with the highest estimated LRI burden.6 All our 
estimates are reported with uncertainty intervals and 
these intervals are larger in areas where we have fewer 
data. We attempt to improve our models by using 
patterns from locations where we do have data and by the 
relationship between LRI mortality and covariates. Many 
of the covariates used in the mortality modelling are also 
part of the risk factor attribution. Risk factors in GBD are 
typically a combination of population­level exposure and 
the relative risk of an outcome. The exposure to each risk 
factor is a covariate in our model. This analysis is 
strengthened by our ability to use risk factors to predict 
time trends in LRI mortality. Yet, the risk factor exposure 
used at multiple points in this analysis are also modelled 
values, dependent on data availability. Although we have 
quantified several interventions for LRI health­loss and 
antibiotic use, we do not explicitly account for health­care 
For WHO guidelines on indoor 
air quality see https://www.who.
int/airpollution/guidelines/
household-fuel-combustion/
IAQ_HHFC_guidelines.pdf
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seeking behaviours, primary health­care availability, and 
specific recommended diagnostics or treatments for LRI. 
Understanding patterns in diagnostics and the use of 
pulse oximetry, chest x­rays, and oxygen therapy might 
reveal additional information about the drivers in LRI 
mortality trends. We do not have a modelled covariate for 
influenza vaccine coverage. Additionally, our model 
quantifies LRI deaths in HIV­negative people only 
because any deaths due to select infectious diseases, 
including LRI, among people with HIV, are classified 
as HIV deaths in the International Classification of 
Diseases; these deaths are captured in the overall HIV­
related mortality estimation in GBD.1 To date, we have 
not separately quantified LRI deaths in HIV­infected 
people. As GBD is an iterative endeavour, we can examine 
this in our future work.
The global reduction in under­5 LRI mortality from 
1990 to 2017 should be viewed as simultaneously a major 
public health achievement and as a call for renewed 
efforts to continue to reduce the burden of disease. 
Declines in LRI burden over time have been highly 
specific by location and are not fully explained by 
improvements in sociodemographic status alone. These 
results illustrate the contribution of improvements in air 
pollution, Hib and PCV vaccine coverage, child nutrition, 
and effective treatment to reducing disease and death 
due to LRI. Quantitative estimates of LRI incidence, 
mortality, and risk factor exposure can serve as a tool to 
sustain the progress made since 1990 and to design 
targeted strategies for countries where high LRI burden 
remains.
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